Which systemic therapy would you use to treat a poorly-differentiated round cell sarcoma with CIC-DUX4 gene fusion?
CIC-DUX4 fusion sarcoma is a rare entity, the aggressiveness of which is comparable to Ewing's sarcoma. A major dilemma is whether to treat these patients with Ewing's like regimen (VDC/IE) or generic sarcoma regimen (AIM).
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Dana-Farber Cancer Institute
Answered on
A patient with a sarcoma such as this should be evaluated at a multidisciplinary sarcoma center, including pathology review. I would favor treating with a Ewing sarcoma regimen as these can be very aggressive tumors. A small series recently reported at the annual CTOS meeting of CIC rearranged small...
Join for free or sign in to see the full answer